Physician profile
Nancy Naghavi
NPI 1811978901
$1,853.78
in general payments reported to CMS, 2019-2025
15 companies · $563 in 2025
The $563 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $185 · 2021: $324 · 2022: $307 · 2023: $139 · 2024: $336 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,037.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $700.68 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $376.34 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.97 | 2020-2025 | Jardiance |
| Exact Sciences Corporation | $97.02 | 2023-2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $95.33 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $62.39 | 2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $57.67 | 2024-2025 | Gvoke Hypopen |
| Lundbeck LLC | $54.30 | 2025 | Rexulti |
| Pfizer INC. | $36.57 | 2025 | |
| Currax Pharmaceuticals LLC | $30.39 | 2022-2025 | Contrave |
| Kowa Pharmaceuticals America, INC. | $28.24 | 2025 | Zoryve |
| Amgen INC. | $27.29 | 2021-2025 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $22.17 | 2025 | Auvelity |
| Alkermes, INC. | $18.03 | 2024 | Vivitrol |
| Janssen Pharmaceuticals, INC | $11.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Naghavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.